Tandem sees sales increase in Q1
By HME News Staff
Updated 9:18 AM CDT, Thu May 1, 2025
SAN DIEGO – Tandem Diabetes Care reported that worldwide sales increased to $234.4 million for its first quarter 2025, an increase of 22% compared to the same quarter in 2024. Pump sales in the U.S. grew by 19% on a GAAP basis and 17% on a non-GAAP basis, on strong shipment growth and average selling price improvement, with the company shipping more than 17,000 pumps in the U.S. and 11,000 outside the U.S. “The strength of our first quarter performance was driven by more than 20% worldwide sales growth, including our highest quarter ever outside the United States,” said John Sheridan, president and CEO. “We are creating new possibilities for people living with diabetes, while delivering record results that align with our 2025 and long-term financial goals for sustained, double-digit sales growth and profitability.” Other highlights in the quarter: a 5-point adjusted EBITDA margin increase; a milestone of approximately 30% of U.S. lives now covered through pharmacy benefits for Tandem Mobi; and a feature in the New England Journal of Medicine on the benefits of Control-IQ Technology for the fourth time.
Comments